1. Home
  2. AKRO vs SYM Comparison

AKRO vs SYM Comparison

Compare AKRO & SYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • SYM
  • Stock Information
  • Founded
  • AKRO 2017
  • SYM 2005
  • Country
  • AKRO United States
  • SYM United States
  • Employees
  • AKRO N/A
  • SYM N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • SYM Industrial Machinery/Components
  • Sector
  • AKRO Health Care
  • SYM Industrials
  • Exchange
  • AKRO Nasdaq
  • SYM Nasdaq
  • Market Cap
  • AKRO 3.9B
  • SYM 3.2B
  • IPO Year
  • AKRO 2019
  • SYM N/A
  • Fundamental
  • Price
  • AKRO $54.20
  • SYM $34.13
  • Analyst Decision
  • AKRO Strong Buy
  • SYM Buy
  • Analyst Count
  • AKRO 6
  • SYM 17
  • Target Price
  • AKRO $82.50
  • SYM $38.60
  • AVG Volume (30 Days)
  • AKRO 1.8M
  • SYM 1.8M
  • Earning Date
  • AKRO 08-08-2025
  • SYM 07-28-2025
  • Dividend Yield
  • AKRO N/A
  • SYM N/A
  • EPS Growth
  • AKRO N/A
  • SYM N/A
  • EPS
  • AKRO N/A
  • SYM N/A
  • Revenue
  • AKRO N/A
  • SYM $2,071,248,000.00
  • Revenue This Year
  • AKRO N/A
  • SYM $24.43
  • Revenue Next Year
  • AKRO N/A
  • SYM $31.15
  • P/E Ratio
  • AKRO N/A
  • SYM N/A
  • Revenue Growth
  • AKRO N/A
  • SYM 42.16
  • 52 Week Low
  • AKRO $21.02
  • SYM $16.32
  • 52 Week High
  • AKRO $58.40
  • SYM $41.76
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 62.96
  • SYM 69.98
  • Support Level
  • AKRO $53.61
  • SYM $30.70
  • Resistance Level
  • AKRO $56.49
  • SYM $38.19
  • Average True Range (ATR)
  • AKRO 2.40
  • SYM 1.98
  • MACD
  • AKRO -0.08
  • SYM 0.43
  • Stochastic Oscillator
  • AKRO 65.93
  • SYM 75.48

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About SYM Symbotic Inc.

Symbotic Inc is an automation technology company that develops technologies to improve operating efficiencies in modern warehouses. The group develops, commercializes, and deploys end-to-end technology solutions that dramatically improve supply chain operations. Th company also automates the processing of pallets and cases in large warehouses or distribution centers for some of the retail and wholesale companies in the world. The company operates in two geographical regions the United States and Canada. Key revenue is generated from the United States.

Share on Social Networks: